These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 16294026

  • 21. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
    Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T.
    Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M.
    Clin Cancer Res; 2006 Apr 15; 12(8):2622-7. PubMed ID: 16638875
    [Abstract] [Full Text] [Related]

  • 23. Pathology of gastrointestinal stromal tumors.
    Hirota S, Isozaki K.
    Pathol Int; 2006 Jan 15; 56(1):1-9. PubMed ID: 16398673
    [Abstract] [Full Text] [Related]

  • 24. C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.
    Gao J, Dang Y, Sun N, Li J, Shen L.
    Med Oncol; 2012 Dec 15; 29(5):3039-45. PubMed ID: 22815156
    [Abstract] [Full Text] [Related]

  • 25. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
    Koh JS, Trent J, Chen L, El-Naggar A, Hunt K, Pollock R, Zhang W.
    Histol Histopathol; 2004 Apr 15; 19(2):565-74. PubMed ID: 15024716
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL, Fletcher CD.
    Hum Pathol; 2007 May 15; 38(5):679-87. PubMed ID: 17437861
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Molecular characterization of an Italian series of sporadic GISTs.
    Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L, Liguria GIST Unit, Bianchi Scarrà G.
    Gastric Cancer; 2013 Oct 15; 16(4):596-601. PubMed ID: 23291969
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P, Fletcher JA, Duensing S, Duensing A.
    Cancer Res; 2007 Mar 15; 67(6):2685-92. PubMed ID: 17363589
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S, Sbaraglia M, Dell'Orto MC, Gasparotto D, Cacciatore M, Boscato E, Carraro V, Toffolatti L, Gallina G, Niero M, Pilozzi E, Mandolesi A, Sessa F, Sonzogni A, Mancini C, Mazzoleni G, Romeo S, Maestro R, Dei Tos AP.
    Oncotarget; 2016 May 24; 7(21):30109-18. PubMed ID: 27097112
    [Abstract] [Full Text] [Related]

  • 34. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK.
    Proc Natl Acad Sci U S A; 2008 Jun 17; 105(24):8387-92. PubMed ID: 18550829
    [Abstract] [Full Text] [Related]

  • 35. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P.
    Gastroenterology; 2005 Feb 17; 128(2):270-9. PubMed ID: 15685537
    [Abstract] [Full Text] [Related]

  • 36. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
    Zheng S, Chen LR, Wang HJ, Chen SZ.
    Hepatogastroenterology; 2007 Dec 17; 54(80):2285-90. PubMed ID: 18265649
    [Abstract] [Full Text] [Related]

  • 37. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P.
    Clin Cancer Res; 2006 Mar 15; 12(6):1743-9. PubMed ID: 16551858
    [Abstract] [Full Text] [Related]

  • 38. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.
    Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y.
    Gastroenterology; 2003 Sep 15; 125(3):660-7. PubMed ID: 12949711
    [Abstract] [Full Text] [Related]

  • 39. [Translational research and diagnosis in GIST].
    Wardelmann E.
    Pathologe; 2012 Nov 15; 33 Suppl 2():273-7. PubMed ID: 22968735
    [Abstract] [Full Text] [Related]

  • 40. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A, Bui B.
    Bull Cancer; 2008 Jan 15; 95(1):107-16. PubMed ID: 18230576
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.